Status:
TERMINATED
Study of the Relationship Between rHuEPO Dose, Serum ADPN, and Mortality in Patients Beginning HD
Lead Sponsor:
Hamamatsu University
Collaborating Sponsors:
Shitoro Clinic
Fujinomiya City Hospital
Conditions:
Renal Dialysis
Eligibility:
All Genders
Brief Summary
Responsiveness of recombinant human erythropoietin (rHuEPO) is known to be related with body fatness in hemodialysis (HD) patients. Adiponectin (ADPN) is inversely associated with body fat mass, and i...
Detailed Description
We selected 85 patients (51 men/34 women, age; 64±15 years) who survived for more than 3 months after the start of HD. After determining initial rHuEPO dosage, we followed the patients for 3 years, an...
Eligibility Criteria
Inclusion
- patients who had first started hemodialysis therapy from August 2000 to May 2001 in 11 dialysis centers in Shizuoka prefecture area.
Exclusion
- nothing particular
Key Trial Info
Start Date :
August 1 2000
Trial Type :
OBSERVATIONAL
End Date :
July 1 2004
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00457535
Start Date
August 1 2000
End Date
July 1 2004
Last Update
April 6 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.